Article Text

PDF

The recurrence rate of venous thromboembolism after a first or second episode of deep venous thrombosis was high
  1. Rebecca J Beyth, MD, MS
  1. Baylor College of Medicine Houston, Texas, USA

    Statistics from Altmetric.com

    
 
 QUESTIONS: For patients who had a first or second episode of confirmed arm or leg deep venous thrombosis (DVT), what is the incidence of recurrent venous thromboembolism (VTE) (DVT or pulmonary embolism [PE]), and what are the risk factors for recurrence?

    Design

    Cohort study with 3.7 to 8.8 years of follow up.

    Setting

    A university hospital in Göteborg, Sweden.

    Patients

    738 patients with DVT confirmed by phlebography or color duplex ultrasonography who had been discharged from the hospital and survived to 1 month. 591 patients (mean age 66 y, 53% women) had a first DVT, and 147 patients had previous VTEs (108 patients with a previous DVT, 19 with a previous PE, and 20 with both DVT and PE). Follow up for mortality was >99%.

    Assessment of prognostic factors

    Data on prognostic factors were collected and used in multivariate analyses: age, sex, duration of oral anticoagulant treatment, location of DVT (arm or leg), level of DVT in leg (distal or proximal), initial antithrombotic treatment, history of VTE, surgery within the past 3 months, immobilisation within 1 week of index DVT, and cancer.

    Main outcome measures

    Recurrent fatal and non-fatal VTE.

    Main results

    During follow up, of the 591 patients in the group who had had a first DVT, 109 (18%) had a recurrent VTE (84 DVTs, 14 non-fatal PEs, and 13 fatal PEs). The mortality rate was 42% overall. Of the 136 patients who had had 1 previous VTE, 37 (27%) had a recurrent VTE (26 DVTs, 9 non-fatal PEs, and 2 fatal PEs). The table shows cumulative incidences for both groups. Multivariate analysis showed that 3 factors increased the risk for recurrent VTE: proximal DVT as an index event (relative risk [RR] 2.30, 95% CI 1.55 to 3.42); cancer (RR 2.21, CI 1.43 to 3.41); and history of VTE (RR 1.71, CI 1.16 to 2.52). 2 factors decreased the risk for recurrent VTE: DVT after surgery (RR 0.27, CI 0.13 to 0.55) and long term anticoagulant treatment (RR 0.95, CI 0.92 to 0.98).

    Cumulative incidence of recurrence of venous thromboembolism after a first or second episode of deep venous thrombosis (DVT)

    Conclusions

    The recurrence rate of venous thromboembolism was high. The risk for recurrence was increased if the index event was a proximal deep venous thrombosis, if the patient had a history of venous thromboembolism or cancer but not recent surgery, or if the duration of the initial anticoagulant treatment period had been short.

    Commentary

    Hansson et al have shown that rates of recurrent VTE remain high despite the standard clinical practice of 3 months of prophylactic oral anticoagulation. Kearon et al eloquently showed that after an initial episode of idiopathic VTE the rate of recurrence was 27.4%/patient year with placebo and 1.3%/patient year with continued warfarin.1 Schulman et al found that prophylactic oral anticoagulation after initial VTE for 6 months rather than 6 weeks reduced recurrence rates.2 Furthermore, long term prophylaxis after a second VTE resulted in lower recurrence rates than did 6 months of prophylaxis, although with more major bleeding.3

    These studies provide compelling evidence that VTE should be viewed as a “chronic polygenic disorder,” 4 with acute exacerbations and that extended prophylactic anticoagulation in patients with idiopathic VTE and VTE associated with persistent risk factors for thrombosis needs to be strongly considered. Hansson et al did not present data on the presence of factor V Leiden, 1 of the most common inherited hypercoagulable states associated with recurrent VTE.5 It is unclear whether long term prophylaxis in patients with factor V Leiden who have an initial VTE is warranted, considering that the risk for anticoagulant related bleeding is directly associated with the duration of treatment.6 The results of an ongoing trial to assess the efficacy of extended low dose warfarin in the secondary prevention of VTE among patients with and without factor V Leiden will, I hope, provide much needed answers.7

    References

    View Abstract

    Footnotes

    • Sources of funding: Swedish Medical Research Council; King Gustav V and Queen Victoria Foundation; Göteborg Medical Association; Göteborg University.

    • For correspondence: Dr P O Hansson, Department of Medicine, Sahlgrenska University Hospital-Östra, SE-41685 Göteborg, Sweden. Fax +46 31 3388694.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.